Overview

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Endothelial Growth Factors
Ophthalmic Solutions
Ranibizumab
Tetrahydrozoline